1,036 results match your criteria Intrahepatic Cholestasis of Pregnancy


Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.

Clin Res Hepatol Gastroenterol 2020 Jul 7. Epub 2020 Jul 7.

Department of Pathology, University of Sherbrooke, Centre hospitalier Universitaire de Sherbrooke (CHUS), Quebec, Canada.

Introduction: Intrahepatic cholestasis of pregnancy (ICP) is a heterogeneous group of liver disorders with a high recurrence rate. Patients with a history of ICP are at risk of developing contraceptive-induced cholestasis, especially if they harbour a biliary transporter mutation. We report the first case of drug-induced cholestasis associated with a contraceptive vaginal ring (CVR) in a patient with a prior history of ICP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2020.06.002DOI Listing

The effects, underlying mechanism and interactions of dexamethasone exposure during pregnancy on maternal bile acid metabolism.

Toxicol Lett 2020 Jun 26. Epub 2020 Jun 26.

Department of Obstetrics and Gynaecology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, 430071, China; Department of Pharmacology, Basic Medical School of Wuhan University, 185 Donghu Road, Wuchang District, Wuhan, 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Diseases, 185 Donghu Road, Wuchang District, Wuhan, 430071, China. Electronic address:

As important members in steroids related signal pathways, bile acids are very important in regulating substance metabolism and immune homeostasis. However, bile acids are highly cytotoxic, and the excessive accumulation can induce several abnormalities such as cholestatic liver injury. It is known that the bile acid metabolism alters during pregnancy and mostly will not result in pathologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2020.06.011DOI Listing

Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia.

Am J Physiol Gastrointest Liver Physiol 2020 Jun 29. Epub 2020 Jun 29.

King's College London.

Intrahepatic cholestasis of pregnancy (ICP) is characterized by elevated maternal circulating bile acid levels and associated dyslipidemia. ICP leads to accumulation of bile acids in the fetal compartment and the elevated bile acid concentrations are associated with an increased risk of adverse fetal outcomes. The farnesoid X receptor agonist, obeticholic acid (OCA) is efficient in the treatment of cholestatic conditions such as primary biliary cholangitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpgi.00126.2020DOI Listing

Ursodeoxycholic acid improves feto-placental and offspring metabolic outcomes in hypercholanemic pregnancy.

Sci Rep 2020 Jun 25;10(1):10361. Epub 2020 Jun 25.

Division of Women and Children's Health, King's College London, London, United Kingdom.

Perturbations in the intrauterine environment can result in lifelong consequences for metabolic health during postnatal life. Intrahepatic cholestasis of pregnancy (ICP) can predispose offspring to metabolic disease in adulthood, likely due to a combination of the effects of increased bile acids, maternal dyslipidemia and deranged maternal and fetal lipid homeostasis. Whereas ursodeoxycholic acid (UDCA) is a commonly used treatment for ICP, no studies have yet addressed whether it can also prevent the metabolic effects of ICP in the offspring and fetoplacental unit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67301-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316783PMC

Liver disease in pregnancy.

Hepatol Res 2020 Jun 24. Epub 2020 Jun 24.

Department of Obstetrics and Gynecology.

Development of liver diseases during pregnancy is not uncommon. They are caused by either a disorder that is unique to pregnancy or an acute or chronic liver disease that already exists or coincidentally develops as a comorbidity of pregnancy. Liver diseases unique to pregnancy include hyperemesis gravidarum; hypertensive disorders of pregnancy, such as pre-eclampsia/eclampsia; hemolysis, elevated liver enzymes, and low platelet count syndrome; intrahepatic cholestasis of pregnancy; and acute fatty liver of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.13540DOI Listing

[A Case of Acute Aortic Dissection Following Intrapartum in a Patient with Marfan ' s Syndrome].

Sichuan Da Xue Xue Bao Yi Xue Ban 2020 May;51(3):438-440

Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.

A 33-year-old woman was admitted at 34 weeks after embryo transfer and over 5 d of cutaneous pruritus. Over 2 years ago, the patient had a third-generation test tube baby due to Marfan's syndrome and gave birth to a live baby girl at full term. This time, the glucose tolerance test during the prenatal examination indicated that the patient was with gestational diabetes, and the blood glucose fluctuated within the normal range after the medical nutrition management and exercise control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12182/20200560603DOI Listing

Coenzyme Q 10 supplementation: A potential therapeutic option for the treatment of intrahepatic cholestasis of pregnancy.

Eur J Pharmacol 2020 Jun 10;882:173270. Epub 2020 Jun 10.

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Argentina. Electronic address:

Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy specific liver disease characterized by pruritus, elevated serum bile acids and abnormal liver function that may be associated with severe adverse pregnancy outcomes. We previously reported that plasma coenzyme Q10 (CoQ10) is decreased in women with ICP as it is its analogue coenzyme Q9 (CoQ9) in rats with ethinyl estradiol (EE)-induced cholestasis. The aim of the present study was to evaluate the possible therapeutic role of CoQ10 in experimental hepatocellular cholestasis and to compare it with ursodeoxycholic acid (UDCA) supplementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2020.173270DOI Listing

Evaluation of predictive value of biochemical markers for adverse obstetrics outcomes in pregnancies complicated by cholestasis.

Ginekol Pol 2020 ;91(5):269-276

Department of Reproduction, Chair of Obstetrics, Gynaecology, and Gynaecological Oncology, Poznan University of Medical Sciences, Poland.

Objectives: Intrahepatic cholestasis of pregnancy (ICP) is significantly more often associated with an abnormal perinatal outcome compared to a group of healthy pregnant women. The aim of the study was to analyse the correlation between the adverse perinatal outcome and the biochemical parameters in pregnancy complicated by cholestasis, and to assess their predictive value for neonatal complications.

Material And Methods: Eighty-six patients with ICP were divided into 3 groups according to their fasting serum bile acid level [group I n = 60, 10-39. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.2020.0051DOI Listing
January 2020

Signalling by lysophosphatidate and its health implications.

Essays Biochem 2020 May 26. Epub 2020 May 26.

Cancer Research Institute of Northern Alberta, Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada.

Extracellular lysophosphatidate (LPA) signalling is regulated by the balance of LPA formation by autotaxin (ATX) versus LPA degradation by lipid phosphate phosphatases (LPP) and by the relative expressions of six G-protein-coupled LPA receptors. These receptors increase cell proliferation, migration, survival and angiogenesis. Acute inflammation produced by tissue damage stimulates ATX production and LPA signalling as a component of wound healing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/EBC20190088DOI Listing

Post-partum Primary Biliary Cholangitis Preceded by Intrahepatic Cholestasis of Pregnancy in Three First Nation Patients.

Dig Dis Sci 2020 May 22. Epub 2020 May 22.

Department of Medicine, Nanaimo General Hospital, Nanaimo, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-020-06333-zDOI Listing

Intrahepatic cholestasis of pregnancy: are fertilization pregnancies at risk?

J Matern Fetal Neonatal Med 2020 May 18:1-6. Epub 2020 May 18.

Department of Obstetrics and Gynecology, Baskent University, Adana, Turkey.

Single pregnancy patients with intrahepatic cholestasis of pregnancy (ICP) were divided into two groups according to the conception method, as spontaneous and fertilization (IVF). We aim to compare the maternal, laboratory and perinatal characteristics of both groups. The records of 10,929 patients who gave birth in the center between October 2011 and July 2019 were analyzed retrospectively from the data processing system records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2020.1765331DOI Listing

Intrahepatic Cholestasis in Pregnancy: Review of the Literature.

J Clin Med 2020 May 6;9(5). Epub 2020 May 6.

Department of Biochemical Diagnostics, Medical University, 15-268 Bialystok, Poland.

Intrahepatic cholestasis of pregnancy (ICP) is the most common hepatic disorder related to pregnancy in women. It usually develops within the third trimester of pregnancy and presents with pruritus as well as elevated levels of bile acid and/or alanine aminotransferase. Clinical signs quickly resolve after delivery; however, there is a high risk of the disorder recurring in subsequent pregnancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9051361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290322PMC

Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.

J Hepatol 2020 May 3. Epub 2020 May 3.

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address:

The ATP binding cassette subfamily B member 4 (ABCB4) gene on chromosome 7 encodes the ABCB4 protein (alias multi drug resistance 3 protein [MDR3]), a P-glycoprotein in the canalicular membrane of the hepatocytes that acts as a translocator of phospholipids into bile. Several variants in ABCB4 have been identified so far that lead to ABCB4 deficiency accounting for a disease spectrum ranging from progressive familial cholestasis type 3 (PFIC-3) to less severe forms presenting as low phospholipid associated cholelithiasis (LPAC), intrahepatic cholestasis of pregnancy (ICP) or drug-induced liver injury (DILI). Furthermore, whole genome sequencing identified ABCB4 variants to be associated with an increased incidence of gallstone disease, gallbladder and cholangiocarcinoma, liver cirrhosis or elevated liver function tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2020.04.036DOI Listing

Circulating Nucleic Acids in Maternal Plasma and Serum in Pregnancy Complications: Are They Really Useful in Clinical Practice? A Systematic Review.

Mol Diagn Ther 2020 May 4. Epub 2020 May 4.

Division of Obstetrics and Prenatal Medicine, Department of Medicine and Surgery (DIMEC) Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Objective: A systematic review was carried out to summarize the available evidence to assess whether circulating nucleic acids in maternal plasma and serum (CNAPS) have the potential to serve as extra and independent markers for the prediction and/or progression monitoring of the most common and severe complications of pregnancy, including preeclampsia, intrauterine growth restriction, preterm delivery, morbidly adherent placenta, gestational diabetes, antiphospholipid syndrome, threatened abortion, intrahepatic cholestasis of pregnancy, and hyperemesis gravidarum.

Method: A comprehensive literature search of the MEDLINE (PubMed), EMBASE, and ISI Web of Knowledge databases was conducted to identify relevant studies that included amounts of CNAPS in the abovementioned pregnancy complications.

Results: Eighty-three studies met the eligibility criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-020-00468-5DOI Listing

The interpretation of liver function tests in pregnancy.

Best Pract Res Clin Gastroenterol 2020 Feb - Apr;44-45:101667. Epub 2020 Feb 18.

Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy. Electronic address:

Abnormal liver tests occur in 3-5% of pregnancies and show many different causes. Although alterations of liver enzymes could be a physiological phenomenon, it may also reflect potential severe liver injury, necessitating further assessment and accurate management. The work-up has to consider liver diseases specific of pregnancy and non pregnancy-related liver damage (coincidental and pre-existing to pregnancy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpg.2020.101667DOI Listing
February 2020

Association between intrahepatic cholestasis of pregnancy and risk of gestational diabetes and preeclampsia: a systematic review and meta-analysis.

Hypertens Pregnancy 2020 Aug 24;39(3):354-360. Epub 2020 Apr 24.

Department of Public Health, Graduate School of Medicine, Osaka University , Osaka, Japan.

Objective: To investigate the association between intrahepatic cholestasis of pregnancy (ICP) and the risk of gestational diabetes mellitus (GDM) and preeclampsia via meta-analysis.

Methods: Pooled odds ratio (OR) and confidence interval (CI) of GDM and preeclampsia for women with ICP were calculated using the fixed- or random-effects model.

Results: Women with ICP were more likely to have GDM (pooled OR = 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10641955.2020.1758939DOI Listing

The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy.

Anticancer Res 2020 Apr;40(4):1997-2001

Department of Biochemical Diagnostics, Medical University, Bialystok, Poland.

Background/aim: The liver of pregnant women undergoes physiological and pathological changes and the changes in liver enzyme activity and release reflect changes in serum enzymatic activity. We aimed to assess the activity of alcohol dehydrogenase (ADH) isoenzymes, and aldehyde dehydrogenase (ALDH) in the sera of women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver disease.

Patients And Methods: Serum samples were taken from 40 women with ICP in the second or third trimester of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14155DOI Listing

A novel etiologic factor of highly elevated cholestanol levels: progressive familial intrahepatic cholestasis.

J Pediatr Endocrinol Metab 2020 May;33(5):665-669

Pediatric Metabolism, Ministry of Health Ankara City Hospital, University of Health Science, Ankara, Turkey.

Background Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an uncommon cholestatic liver disease caused by mutations in the ATP binding cassette subfamily B member 4 (ABCB4) gene. Although PFIC3 is frequently identified in childhood, ABCB4 disease-causing alleles have been described in adults affected by intrahepatic cholestasis of pregnancy, hormone-induced cholestasis, low-phospholipid-associated cholelithiasis syndrome or juvenile cholelithiasis, cholangiocarcinoma and in sporadic forms of primary biliary cirrhosis. Cholestanol is a biomarker which is elevated especially in cerebrotendinous xanthomatosis and rarely in primary biliary cirrhosis (PBC) and Niemann Pick type C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem-2019-0314DOI Listing

Using pregnancy to assess risk and predict women's health.

EClinicalMedicine 2020 Mar 18;20:100292. Epub 2020 Mar 18.

Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eclinm.2020.100292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082210PMC

The Impact of Assisted Reproductive Technology in Twin Pregnancies Complicated by Intrahepatic Cholestasis of Pregnancy: a Retrospective Cohort Study.

Z Geburtshilfe Neonatol 2020 Mar 20. Epub 2020 Mar 20.

Samsun Education and Research Hospital, Obstetrics and Gynecology, Samsun, Turkey.

Introduction: Our study aims to evaluate the perinatal outcomes in twin pregnancies diagnosed with intrahepatic cholestasis of pregnancy (ICP) and to compare these with normal healthy twin pregnancies for perinatal outcomes. The second outcome of the study was to determine whether in vitro fertilization-embryo transfer (IVF-ET) affects the perinatal outcome in ICP patients.

Materials And Methods: In this study, 59 ICP and 641 healthy twin pregnancies were compared for perinatal outcomes retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1129-7358DOI Listing

Ursodeoxycholic acid for adverse perinatal outcomes.

Authors:
Jonathan Ford

Lancet 2020 03;395(10226):780

Leighton Hospital, Mid Cheshire NHS Foundation Trust, Crewe CW1 4QJ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)32988-5DOI Listing

Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy.

Sci Rep 2020 Mar 3;10(1):3895. Epub 2020 Mar 3.

Maternal and Fetal Disease Group, Department of Women and Children's Health, King's College London, London, SE1 1UL, UK.

Ursodeoxycholic acid (UDCA) treatment can reduce itch and lower endogenous serum bile acids in intrahepatic cholestasis of pregnancy (ICP). We sought to determine how it could influence the gut environment in ICP to alter enterohepatic signalling. The gut microbiota and bile acid content were determined in faeces from 35 pregnant women (14 with uncomplicated pregnancies and 21 with ICP, 17 receiving UDCA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-60821-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054423PMC

Unexplained First Trimester Intrahepatic Cholestasis of Pregnancy: A Case Report and Literature Review.

Case Rep Obstet Gynecol 2019 27;2019:4980610. Epub 2019 Dec 27.

American University of Beirut Medical Center, Beirut PO Box: 11-0236, Lebanon.

Intrahepatic cholestasis of pregnancy (ICP) is a condition that usually affects the 3 trimester-pregnant women and is associated with adverse pregnancy outcomes. We present a 31-year-old G2P1 patient with symptoms of ICP as early as 10 weeks of gestation (WG). Her pruritis was initially attributed to eczema. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/4980610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024080PMC
December 2019

New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report.

World J Gastroenterol 2020 Feb;26(5):550-561

Department of Clinical Medicine - Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N DK-8200, Denmark.

Background: Progressive familial intrahepatic cholestasis (PFIC) encompasses a group of autosomal recessive disorders with high morbidity and mortality. Variants in the gene encoding tight junction protein-2 (TJP2) have been linked to PFIC type 4 (PFIC4), which predominantly presents in childhood. However, there are only limited data from adults with TJP2-related PFIC4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v26.i5.550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015721PMC
February 2020

Chronic cholestatic liver disease and pregnancy - not to be confused with intrahepatic cholestasis of pregnancy.

Authors:
G Ajne

BJOG 2020 06 9;127(7):885. Epub 2020 Mar 9.

Department of Obstetrics and Gynaecology, CLINTEC, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1471-0528.16178DOI Listing

Perinatal outcomes of intrahepatic cholestasis during pregnancy: An 8-year case-control study.

PLoS One 2020 19;15(2):e0228213. Epub 2020 Feb 19.

Department of Gynecology and Obstetrics, University Hospital Center Nantes, Nantes, France.

Introduction: Previous studies of fetal effects have suggested that intrahepatic cholestasis of pregnancy is associated with a higher rate of adverse neonatal outcomes including preterm birth, neonatal respiratory distress syndrome, meconium-stained amniotic fluid, neonatal intensive care unit admission, and stillbirth. The objective was to compare the neonatal and maternal consequences in pregnancies affected by intrahepatic cholestasis and normal pregnancies.

Material And Methods: This case-control study compares pregnancies affected by intrahepatic cholestasis (pruritus and bile acid ≥ 10 μmol/L) with low-risk pregnancies managed between December 2006 and December 2014 at a French university hospital center. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228213PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029845PMC

Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels.

Dermatol Ther 2020 Mar 27;33(2):e13272. Epub 2020 Feb 27.

Department of Endoscopy, University Hospital, Kraków, Poland.

The purpose of the work was to assess changes in chemerin and irisin levels in women with diagnosed intrahepatic cholestasis of pregnant women treated with ursodeoxycholic acid. The study group consisted of 50 patients with diagnosed and confirmed intrahepatic cholestasis of pregnant women at 24-25 weeks of pregnancy treatment by ursodeoxycholic acid (UDCA). The study also included a group of 40 pregnant women, without concomitant intrahepatic cholestasis of pregnancy (ICP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13272DOI Listing

Elevated international normalized ratio (INR) and new diagnosis of hepatitis C associated with severe intrahepatic cholestasis of pregnancy (ICP): A case report.

Case Rep Womens Health 2020 Apr 30;26:e00178. Epub 2020 Jan 30.

Maternal Fetal Medicine Penn State Health Milton S. Hershey Medical Center, USA.

Background: Severe intrahepatic cholestasis of pregnancy (ICP), defined as a serum bile acid (SBA) level > 100 μmol/l, remains poorly understood in its mechanism and implications.

Case: A patient with a missed diagnosis of mild ICP went on to develop clinical jaundice and liver function abnormalities in the setting of newly diagnosed hepatitis C and severe ICP on repeat SBA testing.

Conclusion: This case highlights and adds to the growing body of evidence supporting the need for universal screening for hepatitis C in ICP patients and the potential role for repeat SBA testing, which would be a notable change from the traditional care of these individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crwh.2020.e00178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005562PMC

Pregnancy Outcome of Women with Chronic Hepatitis B who Discontinued Antiviral Treatment before or in the Early Pregnancy.

Int J Med Sci 2020 1;17(2):170-175. Epub 2020 Jan 1.

Department of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

The aim of this study was to describe biochemical, virological features and Mother-to child-transmission (MTCT) rate in chronic hepatitis B (CHB) women who stopped antiviral therapy before or in the early pregnancy. This was a single-center, retrospective study. Forty-three CHB women who stopped treatment before or in the early pregnancy and 103 CHB women with tenofovir disoproxil fumarate (TDF) treatment throughout pregnancy were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.38410DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990883PMC
January 2020

Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia.

Arch Gynecol Obstet 2020 03 7;301(3):655-664. Epub 2020 Feb 7.

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Purpose: Intrahepatic cholestasis of pregnancy and preeclampsia are two major pregnancy complications. We aimed to investigate the association between intrahepatic cholestasis of pregnancy (ICP) and preeclampsia.

Methods: Single-center retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-020-05456-yDOI Listing

Liver Disease in Pregnancy: What's New.

Authors:
Carla W Brady

Hepatol Commun 2020 Feb 6;4(2):145-156. Epub 2020 Jan 6.

Division of Gastroenterology Duke University Medical Center Durham NC.

Liver disease in pregnancy may present as a disorder that is unique to pregnancy or as an acute or chronic liver disease occurring coincidentally in pregnancy. Hepatic diseases that are unique to pregnancy include hyperemesis gravidarum; preeclampsia/eclampsia; the syndrome of hemolysis, elevated liver enzymes, and low platelets; intrahepatic cholestasis of pregnancy; and acute fatty liver of pregnancy. Acute and chronic forms of primary hepatic disorders that are seen in pregnancy include viral hepatitis, autoimmune hepatitis, nonalcoholic fatty liver disease, and cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996303PMC
February 2020

A systematic scoping review of clinical indications for induction of labour.

PLoS One 2020 29;15(1):e0228196. Epub 2020 Jan 29.

Centre for Midwifery and Child and Family Health, Faculty of Health, University of Technology Sydney, Australia.

Background: The proportion of women undergoing induction of labour (IOL) has risen in recent decades, with significant variation within countries and between hospitals. The aim of this study was to review research supporting indications for IOL and determine which indications are supported by evidence and where knowledge gaps exist.

Methods: A systematic scoping review of quantitative studies of common indications for IOL. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228196PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988952PMC

Urinary concentrations of phthalate metabolites during gestation and intrahepatic cholestasis of pregnancy: a population-based birth cohort study.

Environ Sci Pollut Res Int 2020 Apr 23;27(11):11714-11723. Epub 2020 Jan 23.

Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, 230032, Anhui, China.

Phthalates, a class of widely used endocrine-disrupting chemicals (EDCs), are toxic to various organ systems in animals and humans. Intrahepatic cholestasis of pregnancy (ICP) is a reversible liver dysfunction causing cholestasis in late pregnancy. Evidence on the associations between exposure to phthalates and ICP is still lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11356-020-07675-xDOI Listing

Does mild intrahepatic cholestasis of pregnancy require an aggressive management? Evidence from a prospective observational study focused on adverse perinatal outcomes and pathological placental findings.

J Matern Fetal Neonatal Med 2020 Jan 19:1-11. Epub 2020 Jan 19.

Unit of Chemistry, Biochemistry and Clinical Molecular Biology, Fondazione Policlinico Universitario "A Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

To ascertain the most effective approach in pregnancies complicated by mild intrahepatic cholestasis of pregnancy (mICP) by evaluating rates of adverse perinatal outcomes (APOs) and pathological placental findings. A total of 89 pregnancies complicated by mICP (defined as total serum bile acids (TSBAs) levels <40 µmol/L) were included. One-drug (ursodeoxycholic acid [UDCA]) ( = 49, 55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2020.1714583DOI Listing
January 2020

Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.

Hepatology 2020 Apr 18;71(4):1474-1485. Epub 2020 Mar 18.

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO.

Liver diseases affecting the mother and infant dyad may present in the perinatal period from 20 weeks of gestation to 28 days of life. This review will focus on the current approach to neonatal acute liver failure and the progress made in the diagnosis and management of gestational alloimmune liver disease. It will highlight mother-to-child transmission of viral hepatitis, both management and public health implications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.31109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150638PMC

Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis.

Hepatobiliary Pancreat Dis Int 2020 Jun 14;19(3):271-276. Epub 2019 Dec 14.

Department of Perinatology, Selcuk University Faculty of Medicine, Konya 42130, Turkey. Electronic address:

Background: Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA).

Methods: This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hbpd.2019.12.001DOI Listing

Outpatient versus inpatient follow-up for intrahepatic cholestasis of pregnancy.

Clin Exp Hepatol 2019 Nov 14;5(4):289-293. Epub 2019 Oct 14.

Department of Obstetrics and Gynecology, Division of Perinatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Aim Of The Study: The optimum management method and the best time of delivery still remain unclear for intrahepatic cholestasis of pregnancy (ICP). We aimed to ascertain whether there is a benefit of close monitoring at hospital.

Material And Methods: We evaluated the maternal and neonatal records of ICPs over a recent five-year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ceh.2019.88616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935849PMC
November 2019

Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"

J Hepatol 2020 Mar 28;72(3):587-588. Epub 2019 Dec 28.

Department of Gastroenterology and Hepatology and Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.11.018DOI Listing

Associations between Maternal Lipid Profiles and Pregnancy Complications: A Prospective Population-Based Study.

Am J Perinatol 2019 Dec 31. Epub 2019 Dec 31.

Department of Nutrition, Food Safety and Toxicology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Objective:  To investigate whether plasma lipid profiles are independently associated with pregnancy complications including gestational diabetes mellitus (GDM), hypertensive disorder complicating pregnancy (HDCP), and intrahepatic cholestasis of pregnancy (ICP).

Study Design:  A prospective study was conducted among 1,704 pregnant women at three medical institutions in Chengdu, China. The concentrations of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured at gestational weeks 12 ± 1, 24 ± 1, and 34 ± 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-3402724DOI Listing
December 2019

UDCA therapy in intrahepatic cholestasis of pregnancy?

J Hepatol 2020 Mar 18;72(3):586-587. Epub 2019 Dec 18.

Department of hepatology and liver transplantation, Asian institute of gastroenterology hospitals, Hyderabad, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.10.025DOI Listing
March 2020
11.336 Impact Factor

Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice.

Oxid Med Cell Longev 2019 15;2019:7419249. Epub 2019 Nov 15.

Department of Histology and Embryology, Anhui Medical University, Hefei, China.

Gestational cholestasis is a common disease and is associated with adverse pregnancy outcomes. However, there are still no effective treatments. We investigated the effects of obeticholic acid (OCA) on fetal intrauterine growth restriction (IUGR) during 17-ethynylestradiol- (E2-) induced gestational cholestasis in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7419249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885290PMC

Correlation of bile acids and aspartate-aminotransferase with outcomes in cholestasis of pregnancy.

J Neonatal Perinatal Med 2019 Nov 23. Epub 2019 Nov 23.

Newark Beth Israel Medical Center, Newark, NJ, USA.

Objective: To identify laboratory data that correlates with poor perinatal outcomes.

Methods: A retrospective chart review of women with intrahepatic cholestasis of pregnancy (ICP), admitted for delivery between January 1, 2013 and December 31, 2017, was performed. Chi-square, student's t-test, and ANOVA statistical analysis was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/NPM-190276DOI Listing
November 2019

Intrahepatic Cholestasis of Pregnancy.

Clin Obstet Gynecol 2020 Mar;63(1):134-151

Department of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio.

Intrahepatic cholestasis of pregnancy is a common disorder of pregnancy manifested by pruritus and elevated bile acids. The etiology of cholestasis is poorly understood and management is difficult due to the paucity of data regarding its diagnosis, treatment, and related adverse outcomes. In this article, we review the epidemiology, pathophysiology, risk factors, laboratory findings, complications, treatment, management, and current evidence surrounding intrahepatic cholestasis of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GRF.0000000000000495DOI Listing

ABCB4 disease: Many faces of one gene deficiency.

Ann Hepatol 2020 Mar - Apr;19(2):126-133. Epub 2019 Oct 31.

Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic; Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and Faculty General Hospital, U Nemocnice, Prague, Czech Republic.

ATP-binding cassette (ABC) subfamily B member 4 (ABCB4), also known as multidrug resistance protein 3 (MDR3), encoded by ABCB4, is involved in biliary phospholipid secretion, protecting hepatobiliary system from deleterious detergent and lithogenic properties of the bile. ABCB4 mutations altering canalicular ABCB4 protein function and expression may have variable clinical presentation and predispose to several human liver diseases. Well-established phenotypes of ABCB4 deficit are: progressive familial intrahepatic cholestasis type 3, gallbladder disease 1 (syn. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aohep.2019.09.010DOI Listing
October 2019

Perinatal death by bile acid levels in intrahepatic cholestasis of pregnancy: a systematic review.

J Matern Fetal Neonatal Med 2019 Nov 19:1-9. Epub 2019 Nov 19.

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Sidney Kimmel Medical College - Thomas Jefferson University, Philadelphia, PA, USA.

Intrahepatic cholestasis of pregnancy (ICP) is characterized by the elevation of total bile acids (TBAs). The primary concern in women with ICP is the increased risk of stillbirth. ICP is generally considered as "mild" when TBA levels range from 10 to 39 µmol/L and "severe" with levels greater than 40 µmol/L, although levels of TBA ≥100 µmol/L have been also considered as a further threshold of severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2019.1685965DOI Listing
November 2019

Role of sphingolipids in the pathogenesis of intrahepatic cholestasis.

Prostaglandins Other Lipid Mediat 2020 04 14;147:106399. Epub 2019 Nov 14.

1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland.

Background & Aims: Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-related liver disorder that affects from 0.2% to 15.6% pregnant women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prostaglandins.2019.106399DOI Listing

Predicting poor outcomes and the need for surgical treatment in neonates with meconium peritonitis.

Prenat Diagn 2020 02 18;40(3):351-357. Epub 2019 Dec 18.

Obstetric & Gynecology Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

Objective: The objective of this study is to determine factors associated with poor outcomes and the need for surgical treatment in neonates with meconium peritonitis (MP).

Methods: We evaluated the association between prenatal ultrasound features, maternal characteristics, and the likelihood of surgery, mortality, and serious morbidity in 49 neonates with a prenatal diagnosis of MP, who were born in Guangzhou Women and Children's Medical Center between January 2011 and December 2016.

Results: Thirty of 49 neonates (61. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pd.5608DOI Listing
February 2020

Maternal and Fetal Outcomes in Pregnancies Complicated by Intrahepatic Cholestasis.

Eurasian J Med 2019 Oct;51(3):270-272

Department of Gynecology and Obstetrics, Atatürk University School of Medicine, Erzurum, Turkey.

Objective: This study aimed to report the maternal and fetal outcomes in women with intrahepatic cholestasis of pregnancy (ICP).

Materials And Methods: The maternal and fetal outcomes in 70 consecutive women who gave birth at Ataturk University Hospital between January 2012 and December 2017 were assessed. The clinical diagnosis of ICP and diagnosis confirmed post-delivery when all the symptoms regressed and laboratory parameters returned to normal was utilized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/eurasianjmed.2019.18447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812911PMC
October 2019
2 Reads